OSE Immunotherapeutics Secures €19.3M Bridge Financing to Extend Cash Runway

Event summary

  • OSE Immunotherapeutics signs term sheet for flexible bridge equity financing with IRIS Capital Investment, potentially raising €19.3M over 24 months.
  • Financing involves issuance of 4,000,000 warrants, representing ~17% of current share capital, at a 5% discount to share price.
  • Cash runway extended to December 2026, with upfront payment of €2M from IRIS.
  • Company defers 2025 Universal Registration Document filing to June 3, 2026, with expected going concern qualification from auditors.
  • Financing is first step in broader strategy to engage institutional investors in US and Europe.

The big picture

OSE Immunotherapeutics' bridge financing reflects a broader trend in biotech of flexible capital raising to extend runways amid uncertain funding environments. The company's shift to a more pragmatic 3-year strategic plan, focusing on chronic pouchitis and ulcerative colitis, aligns with investor expectations for targeted, high-impact indications. The financing comes as OSE navigates governance changes and seeks to stabilize its financial footing ahead of critical clinical milestones.

What we're watching

Cash Runway Dynamics
Whether OSE can secure additional financing beyond 2026 through strategic partnerships or equity offerings.
Clinical Development
The pace at which OSE advances its chronic pouchitis indication and subcutaneous formulation for ulcerative colitis.
Investor Confidence
How institutional investors in the US and Europe respond to OSE's strategic plan and financing needs.